American College of Rheumatology Convergence (ACR)

November 23, 2021

Robert Terkeltaub, MD, explains the results from a phase 2, dose-finding study to determine the safety and efficacy of tigulixostat in patients with gout.

November 22, 2021

Robert F Spiera, MD, explains background mycophenolate treatment and its associated improved outcomes in patients with systemic sclerosis receiving lenabasum.

November 15, 2021

Jeffrey Curtis, MD, MS, MPH, discusses malignancies in older patients with rheumatoid arthritis and cardiovascular risks being treated with either tofacitinib or tumor necrosis factor (TNF) inhibitors.

November 11, 2021

Hermine Brunner, MD, MSc, MBA, discusses secukinumab treatment in patients with enthesitis-related arthritis and juvenile psoriatic arthritis.

November 11, 2021

While statin initiation was associated with reducing the risk of cardiovascular disease, it may increase in the risk of developing diabetes in patients with rheumatoid arthritis.

November 09, 2021

Investigators observed stark contrasts in COVID-19 mRNA vaccination response among inflammatory rheumatic disease patients and the general population.

November 08, 2021

Kyriakos A. Kirou, MD, DSc, FACP, explains the key findings of his upcoming ACR presentation, “COVID-19 Vaccine Antibody Responses in Patients Treated with B-Cell Agents Depend on B-Cell Counts at Time of Vaccine.”

November 08, 2021

"The primary efficacy endpoint was the proportion of patients with disease control without other immunosuppressants and prednisone-equivalent dose of ≤5 mg/day at week 52," Aranow stated.

November 05, 2021

Kazuki Yoshida, MD, MPH, ScD, discusses his ACR presentation entitled, “Comparative Safety of Gout "Treat-to-target" and "Usual Care" Treatment Strategies on Cardiovascular Outcomes Using Observational Data: Causal Inference Approach.”

November 05, 2021

While approximately 80% of patients with rheumatic disease showed humoral immune response rates following the second dose of the COVID-19 vaccine, these numbers were significantly lower than controls.